Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR5A1 | Q13285 | 1/20 | 0.59 |
| ▸ | LTA4H | P09960 | 4/20 | 0.53 |
| ▸ | TP53 | P04637 | 3/20 | 0.53 |
| ▸ | TSHR | P16473 | 1/20 | 0.53 |
| ▸ | PLA2G4B | P0C869 | 5/20 | 0.51 |
| ▸ | NPC1 | O15118 | 2/20 | 0.49 |
| ▸ | RAB9A | P51151 | 2/20 | 0.49 |
| ▸ | HPGD | P15428 | 1/20 | 0.49 |
| ▸ | RARB | P10826 | 3/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | GAA | P10253 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 1/20 | 0.49 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.49 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.49 |
| ▸ | PLA2G4A | P47712 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL927208 | 1.00 | NR5A1 (0.59) | NR5A1LTA4HTP53TSHRPLA2G4B | |
| SCHEMBL3735674 | 1.00 | NR5A1 (0.59) | NR5A1LTA4HTP53TSHRPLA2G4B | |
| SCHEMBL930242 | 0.98 | NR5A1 (0.56) | NR5A1LTA4HTP53TSHRPLA2G4B | |
| SCHEMBL926603 | 0.94 | LTA4H (0.52) | NR5A1LTA4HTP53TSHRNPC1 | |
| SCHEMBL928621 | 0.86 | LTA4H (0.50) | NR5A1LTA4HNPC1RAB9AHPGD | |
| SCHEMBL11095674 | 0.84 | NR5A1 (0.79) | NR5A1LTA4HTP53TSHRPLA2G4B | |
| SCHEMBL8936597 | 0.84 | NR5A1 (0.79) | NR5A1LTA4HTP53TSHRPLA2G4B | |
| SCHEMBL5473083 | 0.84 | NR5A1 (0.79) | NR5A1LTA4HTP53TSHRPLA2G4B | |
| SCHEMBL10943900 | 0.84 | NR5A1 (0.79) | NR5A1LTA4HTP53TSHRPLA2G4B | |
| SCHEMBL2829024 | 0.84 | NR5A1 (0.79) | NR5A1LTA4HTP53TSHRPLA2G4B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7872143-B2 | reacting a Grignard reagent with N-phenyloxycarbonyl-3-cyanopyridinium chloride in a nucleophilic reaction to obtain a 1,2-dihydropyridine intermediate, oxidizing the intermediate with an oxidant (ortho-chloranil) to obtain 2-(4'-alkoxyphenyl)-5-cyanopyridine liquid crystal compounds; two step | FU JEN CATHOLIC UNIVERSITY (TW) | 2011-01-18 | — | — | US | disclosed |
| US-20080306276-A1 | FACILE SYNTHESIS OF A SERIES OF LIQUID CRYSTALLINE 2-(4'-ALKOXYPHENYL)-5-CYANOPYRIDINES | FU JEN CATHOLIC UNIVERSITY (TW) | 2008-12-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080306276-A1 | FACILE SYNTHESIS OF A SERIES OF LIQUID CRYSTALLINE 2-(4'-ALKOXYPHENYL)-5-CYANOPYRIDINES | CLIC4, CBR3, CLCN2 | NR5A1 1489/4885LTA4H 762/4885TP53 3174/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.